Eduardo Carlos
Salido Ruiz
Publikationen, an denen er mitarbeitet Eduardo Carlos Salido Ruiz (6)
2024
-
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131
2018
-
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I
Nature Communications, Vol. 9, Núm. 1
-
Erratum to “A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction” [J Hepatol 67 (2017) 669–679] (S0168827817320469) (10.1016/j.jhep.2017.05.010))
Journal of Hepatology
2017
-
A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction
Journal of Hepatology, Vol. 67, Núm. 4, pp. 669-679
2016
-
Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation
Stem Cell Research, Vol. 16, Núm. 1, pp. 116-119
-
Transient expression of transgenic IL-12 in mouse liver triggers unremitting inflammation mimicking human autoimmune hepatitis
Journal of Immunology, Vol. 197, Núm. 6, pp. 2145-2156